Hydrofluoroalkane as a propellant for pressurized metered-dose inhalers: History, pulmonary deposition, pharmacokinetics, efficacy and safety

Jornal de Pediatria

Volumn 80, Issue 6, 2004, Pages 441-446

  Ibiapina, Cássio C ^a   Cruz, Álvaro A ^b   Camargos, Paulo A M ^a,c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Department of Pediatrics   (Brazil)

Author keywords

Aerosol; Asthma; Hydrofluoralkane; Treatment

Indexed keywords

ANTIASTHMATIC AGENT; APAFLURANE; BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; HFA 227EA; NORFLURANE; PLACEBO; PROPELLANT; SALBUTAMOL; SALMETEROL; BRONCHODILATING AGENT;

AEROSOL; ASTHMA; CANDIDIASIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DATA BASE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPHONIA; HUMAN; HYPOTHALAMUS DISEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METERED DOSE INHALER; OSTEOPENIA; PURPURA; REVIEW; TREATMENT OUTCOME; ADULT; CHILD;

ADULT; AEROSOL PROPELLANTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; HUMANS; HYDROCARBONS, FLUORINATED; METERED DOSE INHALERS;

EID: 28744449669     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/1256     Document Type: Review

References (43)

1. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest. 2001;120:89-93.
2. Dhand R. Future directions in aerosol therapy. Respir Care Clin N Am. 2001;7:319-35.
3. Szefler S, Warner J, Staab D, Wahn U, Bourgeois M, Zandviliet EEM, et al. Switching from conventional aerosol beclomethasone dipropionate therapy in children: a 6-month, open label, randomized trial. J Allergy Clin Immunol. 2002;110:45-50.
4. Terzano C. Pressurized metered dose inhalers and add-on devices. Pulm Pharmacol Ther. 2001;14:351-66.
5. Montreal Protocol. Substances that deplete the ozone layer. Command Paper n. 977. Treaty Series; 1990.
6. Forte R, Dibble C. The role of international environmental agreements in metered-dose inhaler technology changes. J Allergy Clin Immunol. 1999;104:217-20.
7. Meyer RJ. A United States regulator's perspective on the ongoing chlorofluorocarbon transition. J Allergy Clin Immunol. 1999;104:236-8.
8. Atkins P. Chlorofluorocarbon to hydrofluoroalkane formulations: an industry perspective. J Allergy Clin Immunol. 1999;104:268-70.
9. Tashkin DP. Extra-fine corticosteroid aerosols from hydrofluoroalkane- 134a metered-dose inhalers: potential advantages and disadvantages. Chest. 1999;115:316-8.
10. Leach C. Effect of formulation parameters on hydrofluoroalkane- beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:250-2.
11. Brindley A. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. J Allergy Clin Immunol. 1999;104:221-6.
12. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone - A cross-over study in healthy volunteers. Chest. 2002;122:510-6.
13. Janssens H, Jongste J, Hop W, Tiddens H. Extra-fine particles improve lung delivery of inhaled steroids in infants - A study in an upper airway model. Chest. 2003;123:2083-8.
14. Dolovich MB, Fink JB. Aerosols and devices. Respir Care Clin N Am. 2001;7:131-73.
15. Borgstrom L. The pharmacokinetics of inhaled hydrofluoroalkane formulations. J Allergy Clin Immunol. 1999;104:246-9.
16. Leach CL. Preclinical safety of propellant HFA-134a and airomir. Br J Clin Pract. 1995;79:10-2.
17. British Asthma Guidelines Coordinating Committee. British guidelines on asthma management: 1995-review and position statement. Thorax. 1997;52:2-24.
18. Leach CL. Enhanced drug delivery through reformulating IPDM with HFA propellants: drug deposition and its effect on pre clinical and clinical programs. In: Dalby RN, Byron R, Farr SJ, editors. Respiratory drug delivery V proceedings. Buffalo Grove: Interpharm Press; 1996. p. 133-144.
19. Hawksworth RJ, Sykes AP, Faris M, Mant T, Lee TH. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol. 2002;88:473-7.
20. Gustafsson P, Källman S, Whitehead PJ. Clinical equivalence between salbutamol hydrofluoroalkane IPDM and salbutamol Turbuhaler the same cumulative microgram doses in paediatric patients. Respir Med. 2002;96:957-9.
21. Langley SJ, Sykes AP, Batty EP, Masterson CM, Woodcock A. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Ann Allergy Asthma Immunol. 2002;88:488-93.
22. Vondra V, Sladek K, Kotasová J, Terl M, Cantini L. A new HFA-134a propellant in the administration of inhaled DPB via the jet spacer: controlled clinical trial vs the conventional CFC. Respir Med. 2002;96:784-9.
23. Craig-McFeely PM, Wilton LV, Soriano JB, Maier WC, Shakir SAW. Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA 134a in England. Int J Clin Pharmacolol Ther. 2003;41:67-76.
24. Fowler SJ, Orr LC, Sims EJ, Wilson AM, Currie GP, McFarlane L, et al. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest. 2002;122:618-23.
25. Langley SJ, Holden J, Derham A, Hedgeland P, Sharma RK, Woodcock A. Fluticasone propionate via the diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacoline-induced airway yyperresponsiveness. Chest. 2002;122:806-11.
26. Hauber H, Gotfried M, Newman K, Danda R, Servi RJ, Christodoulopoulos P, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol. 2003;112:58-63.
27. Nolting A, Sista S, Abramowitz W. Single dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. J Pharm Sci. 2002;91:424-32.
28. Gillman S, Anolik R, Shenkel E, Newman K. One year trial on safety and normal linear growth with flunisolide HFA in children with asthma. Clin Pediatric. 2002;41:333-40.
29. Currie GP, Stenback S, Lipworth BJ. Effects of fluticasne vs. fluticasone/salmeterol on airway calibre and airway hiperresponsiveness in mild persistent asthma. Br J Clin Pharmacol. 2003;56:11-17.
30. Ganderton D, Lewis D, Davier R, Meakin B, Brambilla G, Church T. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med. 2002;96:3-8.
31. Woodcock A, Acerbi D, Poli G. Moduliteâ technology: pharmacodynamic and pharmacokinetic implications. Respir Med. 2002;96:9-15.
32. Bousquet J, Cantini L. Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (DPB Modulite). Respir Med. 2002;96:17-27.
33. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane- 134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest. 1999;115:343-51.
34. Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol: comparative Inhaled Steroid Investigation Group (CISIG). Respir Med. 2000;94:549-55.
35. Farmer IS, Middle M, Savic J, Perri VL, Herdman MJ. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Eeasibreathe inhaler for the treatment of paediatric asthma. Respir Med. 2000;94:57-63.
36. Lipworth BJ. The comparative safety/efficacy ratio of HFA-DPB. Respir Med. 2000;94:21-6.
37. Cruz AA, Ponte EV. Inflamação nas pequenas vias aéreas em asmáticos. Rev Bras Alerg Imunupatol. 2003;26:25-32.
38. Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Van Essen-Zandvliet E, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics. 2002;109:1-10.
39. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol. 2000;106:1209-26.
40. Harrison LI, Colice GL, Donnell D, Soria I, Dockhorn R. Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. J Pharm Pharmacol. 1999;51:263-9.
41. Price D, Haughney J, Duerden M, Nicholls C, Moseley C. The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics 2002;20:653-64.
42. Donohoe H. Preparing patients and health professionals for the transition to chlorofluorocarbon-free inhalers: the British perspective. J Allergy Clin Immunol. 1999;104:239-42.
43. Hartung TK, Allbutt H, Dewar M, Innes JA, Cromptom GK. Moving from CFC aerosol to HFA aerosol or dry powder inhalers: What do patients think? Respiration. 2002;69:314-9.